Chelsea ANDA withdrawals
Executive SummaryFDA is proposing to withdraw nine ANDAs of the West Hempstead, New York-based generics manufacturer on the grounds that the applications contained untrue statements and that the products are not safe and effective. The ANDAs include verapamil 80 mg and 120 mg tablets (Calan), disopyramide 100 mg and 150 mg capsules (Norpace), perphenazine 4 mg/amitriptyline 50 mg tablets (Tiavil), oxazepam 10, 15 and 30 mg tablets (Serax), and perphenzing 8 mg tablets (Tilafon). Chelsea has until July 23 to request a hearing.
You may also be interested in...
Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further.
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.